Moderna and Merck & Co: mRNA Cancer Vaccine Shows “Highly Encouraging Results,” Shares Rise
On Tuesday, Moderna (NASDAQ: MRNA) announced that their personalized cancer-vaccine program was successful in a midstage study of skin-cancer patients.
Read more